Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Puerto Rico Tax-Haven Status, R&D Credit Weakened By Tax-Reform Bill

Executive Summary

Under tax reform legislation recently passed by Congress, a 20% tax on products made in domestic territories will adversely affect the many device firms with Puerto Rican plants that currently enjoy a lower, 4% tax rate on profits. And a second tax provision usually relied upon by medtech companies, the R&D tax credit, also loses ground under the final Senate bill passed Dec. 2.

You may also be interested in...



'Big Shoes To Fill' As Hatch Retirement Leaves Supplement Market Legacy

Sen. Orrin Hatch won’t seek re-election and will leave 24 years after Congress passed the Dietary Supplement Health and Education Act as a framework for FDA's regulation of vitamin, mineral and supplement product manufacturing and marketing. Hatch is in his seventh term and is the longest-serving Senate member.

Conferees Kill Corporate AMT In Tax Bill, Freeing Use Of R&D Credits

Members of a tax reform bill conference committee repealed a controversial corporate alternative minimum tax, which will allow more device firms to take advantage of research & development tax credits. That was one of several changes made to help win the tax bill's final passage, anticipated this week.

Medtech To Benefit From 20% Corporate Rate, Tax-Free Foreign Transfers In Pending US Tax Bill

Medical device firms will benefit from a Republican tax bill that has passed the full US House and a key Senate committee. The bill lowers the corporate tax rate to 20% from a maximum of 35%, treats foreign-earned intangible income at a favorably low rate of 12.5%, and permits tax-free transfers of intangible corporate property, such as patents, from foreign firms to US parents.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT121858

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel